Gamco Investors INC. ET AL increased its holdings in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 34.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 220,000 shares of the company’s stock after purchasing an additional 56,000 shares during the period. Gamco Investors INC. ET AL owned 0.52% of Meridian Bioscience worth $2,088,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in VIVO. Nuveen Asset Management LLC purchased a new stake in Meridian Bioscience during the 2nd quarter worth $3,251,000. D. E. Shaw & Co. Inc. boosted its position in Meridian Bioscience by 61.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 619,878 shares of the company’s stock worth $7,364,000 after purchasing an additional 235,171 shares during the period. Marshall Wace LLP boosted its position in Meridian Bioscience by 285.5% during the 2nd quarter. Marshall Wace LLP now owns 312,886 shares of the company’s stock worth $3,717,000 after purchasing an additional 231,721 shares during the period. Acadian Asset Management LLC boosted its position in Meridian Bioscience by 255.9% during the 2nd quarter. Acadian Asset Management LLC now owns 320,309 shares of the company’s stock worth $3,804,000 after purchasing an additional 230,299 shares during the period. Finally, State of New Jersey Common Pension Fund D boosted its position in Meridian Bioscience by 301.2% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 200,600 shares of the company’s stock worth $1,904,000 after purchasing an additional 150,600 shares during the period. 88.20% of the stock is owned by hedge funds and other institutional investors.
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. ValuEngine raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. BidaskClub raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, October 16th. Finally, Canaccord Genuity reaffirmed a “sell” rating and set a $9.00 price target on shares of Meridian Bioscience in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $11.25.
Meridian Bioscience (NASDAQ:VIVO) last issued its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.04. The firm had revenue of $50.80 million during the quarter, compared to analysts’ expectations of $50.57 million. Meridian Bioscience had a net margin of 12.65% and a return on equity of 17.82%. The firm’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same period last year, the firm posted $0.20 earnings per share. Sell-side analysts predict that Meridian Bioscience, Inc. will post 0.64 EPS for the current year.
Meridian Bioscience Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Recommended Story: What is range trading?
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.